<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5631365</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx163.1159</article-id><article-id pub-id-type="publisher-id">ofx163.1159</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Poster Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>Enhanced Potency and Durability of Antibody Response to Seasonal Trivalent Inactivated Influenza Vaccine (TIV) Combined with a Novel Water-in-Oil Adjuvant System at Reduced Hemagglutinin (HA) Doses</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gorse</surname><given-names>Geoffrey J</given-names></name><degrees>MD, FIDSA</degrees><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Grimes</surname><given-names>Stephen</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Buck</surname><given-names>Helen</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Mulla</surname><given-names>Hussain</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>White</surname><given-names>Peter</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Graham</surname><given-names>Irene</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Treanor</surname><given-names>John J</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Hill</surname><given-names>Heather</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="AF0007">7</xref></contrib><contrib contrib-type="author"><name><surname>May</surname><given-names>Jeanine</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0007">7</xref></contrib><contrib contrib-type="author"><name><surname>Blackburn</surname><given-names>Peter</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>VA St. Louis Health Care System</institution>, <addr-line>St. Louis, Missouri</addr-line></aff><aff id="AF0002">
<label>2</label>
<institution>Saint Louis University School of Medicine</institution>, <addr-line>St. Louis, Missouri</addr-line></aff><aff id="AF0003">
<label>3</label>
<institution>Mercia Pharma, Inc.</institution>, <addr-line>New York, New York</addr-line></aff><aff id="AF0004">
<label>4</label>
<institution>Nova Immunotherapeutics Limited</institution>, <addr-line>Leicestershire</addr-line>, <country>United Kingdom</country></aff><aff id="AF0005">
<label>5</label>
<institution>Internal Medicine, Division of Infectious Diseases, Saint Louis University</institution>, <addr-line>Saint Louis, Missouri</addr-line></aff><aff id="AF0006">
<label>6</label>
<institution>Medicine, University of Rochester Medical Center School of Medicine and Dentistry</institution>, <addr-line>Rochester, New York</addr-line></aff><aff id="AF0007">
<label>7</label>
<institution>EMMES Corporation</institution>, <addr-line>Rockville, Maryland</addr-line></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 161. Influenza and Influenza Vaccines</p><p>
<italic>Friday, October 6, 2017: 12:30 PM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S455</fpage><lpage>S455</lpage><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx163.1159.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>New influenza vaccines are needed to increase vaccine efficacy against infection and illness. Adjuvants may allow HA dose-sparing while increasing the antibody response. MAS-1 is an investigational low viscosity, free-flowing, water-in-oil emulsion-based adjuvant delivery system with stable nanoglobular droplets whether manufactured in bulk or at point-of-use (POU). MAS-1 oily vehicle is stable for at least 5 years at room temperature, in bulk or POU vials.</p></sec><sec id="s2"><title>Methods</title><p>A phase 1, double-blind, single-center, safety and immunogenicity, HA dose escalation trial was conducted. 1, 3, 5 or 9 &#x000b5;g per HA from the licensed 2014/15 seasonal TIV prepared POU with a fixed dose of MAS-1 adjuvant in 0.3 mL emulsion compared with standard dose (SD, 15 &#x000b5;g per HA) TIV in 0.5 mL was injected IM on day 1. Safety was measured by reactogenicity, adverse events, and safety labs. Serum hemagglutination inhibition (HAI) antibody titers were measured at 5 time points post-vaccination.</p></sec><sec id="s3"><title>Results</title><p>72 subjects, age 18&#x02013;47 years, were randomly assigned to either adjuvanted vaccine or TIV in a 2:1 ratio. The 1 and 3 &#x000b5;g per HA cohorts were enrolled together, then the 5 &#x000b5;g follo wed by the 9 &#x000b5;g per HA cohorts. Common injection site reactions were mild tenderness (74%) and pain (54%), resolving by 5 days post-vaccination. Common systemic reactions were mild headache (36%), myalgia (19%), malaise (18%) and fatigue (18%) through day 14 post-vaccination. Safety labs were not concerning. Geometric mean antibody titers against component strains were higher, of longer duration and peaked later in the adjuvanted vaccine groups than with SD TIV (Figures 1 &#x02013; 3). Seroconversion rates (%) had a similar pattern:</p><table-wrap id="T1" orientation="portrait" position="float"><table frame="box" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Vaccine</th><th align="center" valign="bottom" rowspan="1" colspan="1">Subjects (N)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Days Post-Vaccination</th><th align="center" valign="bottom" rowspan="1" colspan="1">A/H1
(%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">A/H3
(%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">B
(%)</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="1" colspan="1">1&#x000b5;g HA+MAS-1</td><td align="center" valign="bottom" rowspan="1" colspan="1">12</td><td align="center" valign="bottom" rowspan="1" colspan="1">14</td><td align="center" valign="bottom" rowspan="1" colspan="1">25</td><td align="center" valign="bottom" rowspan="1" colspan="1">33.3</td><td align="center" valign="bottom" rowspan="1" colspan="1">25</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">28</td><td align="center" valign="bottom" rowspan="1" colspan="1">33.3</td><td align="center" valign="bottom" rowspan="1" colspan="1">41.7</td><td align="center" valign="bottom" rowspan="1" colspan="1">41.7</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">84</td><td align="center" valign="bottom" rowspan="1" colspan="1">50</td><td align="center" valign="bottom" rowspan="1" colspan="1">60</td><td align="center" valign="bottom" rowspan="1" colspan="1">40</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">3&#x000b5;g HA+MAS-1</td><td align="center" valign="bottom" rowspan="1" colspan="1">12</td><td align="center" valign="bottom" rowspan="1" colspan="1">14</td><td align="center" valign="bottom" rowspan="1" colspan="1">33.3</td><td align="center" valign="bottom" rowspan="1" colspan="1">25</td><td align="center" valign="bottom" rowspan="1" colspan="1">25</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">28</td><td align="center" valign="bottom" rowspan="1" colspan="1">33.3</td><td align="center" valign="bottom" rowspan="1" colspan="1">50</td><td align="center" valign="bottom" rowspan="1" colspan="1">33.3</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">84</td><td align="center" valign="bottom" rowspan="1" colspan="1">33.3</td><td align="center" valign="bottom" rowspan="1" colspan="1">50</td><td align="center" valign="bottom" rowspan="1" colspan="1">16.7</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">5&#x000b5;g HA+MAS-1</td><td align="center" valign="bottom" rowspan="1" colspan="1">12</td><td align="center" valign="bottom" rowspan="1" colspan="1">14</td><td align="center" valign="bottom" rowspan="1" colspan="1">41.7</td><td align="center" valign="bottom" rowspan="1" colspan="1">41.7</td><td align="center" valign="bottom" rowspan="1" colspan="1">50</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">28</td><td align="center" valign="bottom" rowspan="1" colspan="1">50</td><td align="center" valign="bottom" rowspan="1" colspan="1">58.3</td><td align="center" valign="bottom" rowspan="1" colspan="1">50</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">84</td><td align="center" valign="bottom" rowspan="1" colspan="1">50</td><td align="center" valign="bottom" rowspan="1" colspan="1">58.3</td><td align="center" valign="bottom" rowspan="1" colspan="1">58.3</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">9&#x000b5;g HA+MAS-1</td><td align="center" valign="bottom" rowspan="1" colspan="1">12</td><td align="center" valign="bottom" rowspan="1" colspan="1">14</td><td align="center" valign="bottom" rowspan="1" colspan="1">66.7</td><td align="center" valign="bottom" rowspan="1" colspan="1">50</td><td align="center" valign="bottom" rowspan="1" colspan="1">66.7</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">28</td><td align="center" valign="bottom" rowspan="1" colspan="1">66.7</td><td align="center" valign="bottom" rowspan="1" colspan="1">50</td><td align="center" valign="bottom" rowspan="1" colspan="1">66.7</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">84</td><td align="center" valign="bottom" rowspan="1" colspan="1">75</td><td align="center" valign="bottom" rowspan="1" colspan="1">75</td><td align="center" valign="bottom" rowspan="1" colspan="1">66.7</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">15&#x000b5;g HA SD TIV</td><td align="center" valign="bottom" rowspan="1" colspan="1">24</td><td align="center" valign="bottom" rowspan="1" colspan="1">14</td><td align="center" valign="bottom" rowspan="1" colspan="1">29.2</td><td align="center" valign="bottom" rowspan="1" colspan="1">45.8</td><td align="center" valign="bottom" rowspan="1" colspan="1">25</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">28</td><td align="center" valign="bottom" rowspan="1" colspan="1">25</td><td align="center" valign="bottom" rowspan="1" colspan="1">33.3</td><td align="center" valign="bottom" rowspan="1" colspan="1">20.8</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">84</td><td align="center" valign="bottom" rowspan="1" colspan="1">13</td><td align="center" valign="bottom" rowspan="1" colspan="1">26.1</td><td align="center" valign="bottom" rowspan="1" colspan="1">8.7</td></tr></tbody></table></table-wrap></sec><sec id="s7"><title>Conclusion</title><p>MAS-1 adjuvant provided HA dose-sparing without significant systemic or local safety concerns, higher HAI antibody titers and seroconversion rates for a longer duration than SD TIV, and could conceivably contribute to greater vaccine efficacy.</p><fig fig-type="figure" id="F1" orientation="portrait" position="float"><graphic xlink:href="OFIDIS_ofx163_IF0506"/></fig><fig fig-type="figure" id="F2" orientation="portrait" position="float"><graphic xlink:href="OFIDIS_ofx163_IF0507"/></fig><fig fig-type="figure" id="F3" orientation="portrait" position="float"><graphic xlink:href="OFIDIS_ofx163_IF0508"/></fig></sec><sec id="s5"><title>Disclosures</title><p>
<bold>G. J. Gorse</bold>, Nova Immunotherapeutics Limited: Principal Investigator at Saint Louis University, Funding to Saint Louis University for the clinical study; <bold>S. Grimes</bold>, Mercia Pharma, Inc.: Employee and Principal Scientist, Salary; <bold>H. Buck</bold>, Nova Immunotherapeutics Limited: Consultant, Consulting fee; <bold>H. Mulla</bold>, Nova Immunotherapeutics Limited: Employee, Salary; <bold>P. White</bold>, Nova Immunotherapeutics Limited: Employee, Salary; Mercia Pharma, Inc.: Shareholder, Licensing agreement or royalty; <bold>P. Blackburn</bold>, Mercia Pharma, Inc.: President and CSO, Salary</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>